IZCZ-3
Based on 2 publication(s) in Google Scholar
IZCZ-3 is a potent c-MYC transcription inhibitor with antitumor activity.
For research use only. We do not sell to patients.
- Purity: 99.74%
- CAS No.: 2223019-53-0
- Formula: C46H49N7O
- Molecular Weight:715.93
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
Anti-Cancer Compound Library
HY-L025
-
Autophagy Compound Library
HY-L029
-
Glutamine Metabolism Compound Library
HY-L064
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Transcription Factor-Targeted Library
HY-L090
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Cancer Stem Cells Compound Library
HY-L135
-
Mitochondrial Protection Compound Library
HY-L144
-
Cell Death Library
HY-L162
-
Anti-Ovarian Cancer Compound Library
HY-L173
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Cell Proliferation Compound Library
HY-L201
-
Lactic Acid Metabolic Compound Library
HY-L204
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) IZCZ-3
More
Customer Validation & Images
-
WB
Biological Activity
c-MYC transcription[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A-375 | IC50 |
4.2 μM
Compound: IZCZ-3
|
Cytotoxicity against human A375 cells assessed as reduction in cell viability after 24 hrs by MTT assay
Cytotoxicity against human A375 cells assessed as reduction in cell viability after 24 hrs by MTT assay
|
[PMID: 29474069] |
| BJ | IC50 |
15.9 μM
Compound: IZCZ-3
|
Cytotoxicity against human BJ cells assessed as reduction in cell viability after 24 hrs by MTT assay
Cytotoxicity against human BJ cells assessed as reduction in cell viability after 24 hrs by MTT assay
|
[PMID: 29474069] |
| HBL-100 | IC50 |
11.2 μM
Compound: 1; IZCZ-3
|
Cytotoxicity against human HBL-100 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
Cytotoxicity against human HBL-100 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
|
[PMID: 36121464] |
| HeLa | IC50 |
2.1 μM
Compound: IZCZ-3
|
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay
|
[PMID: 29474069] |
| HepG2 | IC50 |
6.1 μM
Compound: 1; IZCZ-3
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
|
[PMID: 36121464] |
| Huh-7 | IC50 |
4.1 μM
Compound: IZCZ-3
|
Cytotoxicity against human Huh7 cells assessed as reduction in cell viability after 24 hrs by MTT assay
Cytotoxicity against human Huh7 cells assessed as reduction in cell viability after 24 hrs by MTT assay
|
[PMID: 29474069] |
| MDA-MB-231 | IC50 |
5.1 μM
Compound: 1; IZCZ-3
|
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
|
[PMID: 36121464] |
| SiHa | IC50 |
3.3 μM
Compound: IZCZ-3
|
Cytotoxicity against human SiHa cells assessed as reduction in cell viability after 24 hrs by MTT assay
Cytotoxicity against human SiHa cells assessed as reduction in cell viability after 24 hrs by MTT assay
|
[PMID: 29474069] |
| U2OS | IC50 |
6.8 μM
Compound: IZCZ-3
|
Cytotoxicity against human U2OS cells assessed as reduction in cell viability after 24 hrs by MTT assay
Cytotoxicity against human U2OS cells assessed as reduction in cell viability after 24 hrs by MTT assay
|
[PMID: 29474069] |
IZCZ-3 (2.1 μM-15.9 μM; 24 hours) significantly inhibits SiHa, HeLa, Huh7, and A375 cancer cell proliferation (IC50s of 3.3, 2.1，4.1, and 4.2 μM, respectively). IZCZ-3 induces only weak growth inhibition in the BJ fibroblasts (IC50=15.9 μM) and mouse mesangial cells (IC50=15.6 μM), suggesting that IZCZ-3 is more effective against cancer cells than against c-MYC-independent normal cells[1].
?
IZCZ-3 (0-5 μM; 12 hours) induces an apparent accumulation of cells in the G0/G1 phase in SiHa cells in a dose-dependent manner[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:SiHa, HeLa, Huh7, and A375 cancer cells (with overexpression of c-MYC protein) and in normal BJ fibroblasts and primary cultured mouse mesangial cells (with relatively low expression of c-MYC protein).
-
Concentration:2.1 μM-15.9 μM
-
Incubation Time:24 hours
-
Result:IC50s of 3.3, 2.1，4.1, and 4.2 μM for SiHa, HeLa, Huh7, and A375 cancer cells; IC50s of 15.9 μM and 15.6 μM for BJ fibroblasts and mouse mesangial cells.
-
Cell Line:SiHa cells
-
Concentration:0, 1.25, 2.5, and 5 μM
-
Incubation Time:12 hours
-
Result:Induced an apparent accumulation of cells in the G0/G1 phase (increasing from 61% to 70%) in a dose-dependent manner.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude mice (5 weeks old) bearing SiHa human cervical squamous cancer xenograft model[1]
-
Dosage:20, 10, and 5 mg/kg
-
Administration:Treated intraperitoneally; every other day for 24 days
-
Result:Treatment with 20, 10, and 5 mg/kg resulted in a significant reduction in tumor weight with tumor growth inhibition (TGI) of 69%, 64%, and 57%, respectively. Displayed time-dependent inhibition of tumor growth.
Chemical Information
-
CAS No. 2223019-53-0
-
Appearance Solid
-
Molecular Weight 715.93
-
Formula C46H49N7O
-
Color Off-white to pink
-
SMILES
CN(CC1)CCN1C2=CC=C(C3=C(C4=CC=C(N5CCN(C)CC5)C=C4)N=C(C6=CC(C(C=CC=C7)=C7N8CC)=C8C=C6)N3C9=CC=C(OC)C=C9)C=C2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Oncogene
A novel network pharmacology approach for leukaemia differentiation therapy using Mogrify®. [Abstract]2022 Nov;41(48):5160-5175. PMID: 36271030
IZCZ-3 purchased from MedChemExpress. Usage Cited in: Oncogene. 2022 Nov;41(48):5160-5175. [Abstract]
IZCZ-3 (0.5 μM; 24 h) co-operates with IFNγ to induce differentiation in NB4 cells.
-
Cell Biol Toxicol
Long non-coding RNA CTSLP8 mediates ovarian cancer progression and chemotherapy resistance by modulating cellular glycolysis and regulating c-Myc expression through PKM2. [Abstract]2022 Dec;38(6):1027-1045. PMID: 34510316
Solvent & Solubility
DMSO : 5 mg/mL (6.98 mM; ultrasonic and warming and heat to 80°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (281 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.3968 mL | 6.9839 mL | 13.9678 mL | 34.9196 mL |
| 5 mM | 0.2794 mL | 1.3968 mL | 2.7936 mL | 6.9839 mL |
Powered by Bioz